ESC 2025: Acoramidis may reduce AF/flutter burden in ATTR-CM, per new ATTRibute-CM trial analysis discussed by CardioNerds.
CardioNerds
The CardioNerds—Amit Goyal, MD, and Daniel Ambinder, MD—cover cardiology concepts in an engaging format that features leaders in the industry, as well as up-and-coming voices in residency and fellowship. They aim to improve health equitably by providing timely and insightful cardiovascular health news.
Advertisement
CTA-first screening before TAVR avoids invasive angiography in 53% of patients—without compromising outcomes.
Delays in TAVI for acute decompensated aortic stenosis worsen outcomes.
Explore evolving LV unloading strategies in AMI shock with The CardioNerds.
Pulmonary air embolism causing RV failure & arrest—via ocular route? A rare case, deep dive, with The CardioNerds.
NAVULTRA registry compares Navitor vs. SAPIEN 3 Ultra in TAVR, revealing key tradeoffs in pacemaker use, PVL, and HF outcomes
Dr. Daniel Judge discusses how the ATTRibute-CM trial marks a turning point in ATTR cardiomyopathy treatment and research.
The FDA approved the use of Edwards Lifesciences' SAPIEN 3 TAVR platform for patients with severe aortic stenosis.
Dr. Dan Judge speaks to The CardioNerds about his interpretation of the primary findings from ATTRibute-CM.
Dr. Daniel Judge talks to the CardioNerds about a pivotal study in ATTR-CM.
A multifaceted approach is necessary to reduce the deaths of smoking-related aortic aneurysms.
Advertisement
Cardio Care Today delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest updates from Cardio Care Today experts, including the CardioNerds.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.